Microscopic colitis and risk of incident rheumatoid arthritis: A nationwide population-based matched cohort study

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2023-09-20 DOI:10.1111/apt.17708
David Bergman, Bjorn Roelstraete, Jiangwei Sun, Fahim Ebrahimi, Johan Askling, Jonas F. Ludvigsson
{"title":"Microscopic colitis and risk of incident rheumatoid arthritis: A nationwide population-based matched cohort study","authors":"David Bergman,&nbsp;Bjorn Roelstraete,&nbsp;Jiangwei Sun,&nbsp;Fahim Ebrahimi,&nbsp;Johan Askling,&nbsp;Jonas F. Ludvigsson","doi":"10.1111/apt.17708","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Microscopic colitis (MC) has been linked to several autoimmune conditions. Results from previous studies on the association with rheumatoid arthritis (RA) have been inconsistent.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>To assess the risk of future RA in MC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a nationwide matched cohort study in Sweden of 8179 patients with biopsy-verified MC (diagnosed in 2007–2017), 36,400 matched reference individuals and 8202 siblings without MC, with follow-up until 2021. Information on MC was obtained from all of Sweden's regional pathology registers (<i>n</i> = 28) through the ESPRESSO cohort. Data on incident RA were collected from the National Patient Register. Using Cox regression, we calculated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During a median follow-up of 9.1 years (interquartile range = 6.7–11.7), 73 MC patients and 183 reference individuals from the general population were diagnosed with RA (99 vs. 55 events per 100,000 person-years), equivalent to one extra case of RA in 226 patients with MC followed for 10 years. These rates corresponded to an aHR of 1.83 (95% CI = 1.39–2.41). The aHR was highest during the first year of follow-up (2.31 [95% CI = 1.08–4.97]) and remained significantly elevated up to 5 years after MC diagnosis (aHR 2.16; 95% CI = 1.42–3.30). Compared to siblings, without MC, the aHR was 2.04 (95% CI = 1.18–3.56).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Patients with MC are at a nearly two-fold risk of developing RA compared to the general population. Knowledge of this increased risk may expedite evaluation for RA in patients with MC presenting with joint symptoms and/or arthralgia, thus preventing delay until RA diagnosis.</p>\n </section>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"58 10","pages":"1028-1040"},"PeriodicalIF":6.6000,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.17708","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.17708","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Microscopic colitis (MC) has been linked to several autoimmune conditions. Results from previous studies on the association with rheumatoid arthritis (RA) have been inconsistent.

Aim

To assess the risk of future RA in MC.

Methods

We conducted a nationwide matched cohort study in Sweden of 8179 patients with biopsy-verified MC (diagnosed in 2007–2017), 36,400 matched reference individuals and 8202 siblings without MC, with follow-up until 2021. Information on MC was obtained from all of Sweden's regional pathology registers (n = 28) through the ESPRESSO cohort. Data on incident RA were collected from the National Patient Register. Using Cox regression, we calculated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs).

Results

During a median follow-up of 9.1 years (interquartile range = 6.7–11.7), 73 MC patients and 183 reference individuals from the general population were diagnosed with RA (99 vs. 55 events per 100,000 person-years), equivalent to one extra case of RA in 226 patients with MC followed for 10 years. These rates corresponded to an aHR of 1.83 (95% CI = 1.39–2.41). The aHR was highest during the first year of follow-up (2.31 [95% CI = 1.08–4.97]) and remained significantly elevated up to 5 years after MC diagnosis (aHR 2.16; 95% CI = 1.42–3.30). Compared to siblings, without MC, the aHR was 2.04 (95% CI = 1.18–3.56).

Conclusion

Patients with MC are at a nearly two-fold risk of developing RA compared to the general population. Knowledge of this increased risk may expedite evaluation for RA in patients with MC presenting with joint symptoms and/or arthralgia, thus preventing delay until RA diagnosis.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
显微镜下结肠炎与类风湿性关节炎发病风险:一项基于全国人群的匹配队列研究。
背景:显微镜下结肠炎(MC)与多种自身免疫性疾病有关。先前关于类风湿性关节炎(RA)的研究结果并不一致。目的:评估MC未来患RA的风险。方法:我们在瑞典进行了一项全国性的匹配队列研究,共有8179名经活检证实的MC患者(2007-2017年诊断)、36400名匹配参考个体和8202名无MC的兄弟姐妹,随访至2021年。MC的信息来自瑞典所有的地区病理学登记册(n = 28)通过ESPRESSO队列。从国家患者登记处收集有关RA事件的数据。使用Cox回归,我们计算了调整后的风险比(aHR)和95%置信区间(CI)。结果:中位随访9.1 年(四分位间距 = 6.7-11.7),73名MC患者和183名来自普通人群的参考个体被诊断为RA(每100000人-年发生99例与55例事件),相当于226名MC患者中多出一例RA,随访10年 年。这些比率对应于1.83的aHR(95%置信区间 = 1.39-2.41)。aHR在随访的第一年最高(2.31[95%CI = 1.08-4.97]),并且在高达5 MC诊断后数年(aHR 2.16;95%CI = 1.42-3.30)。与没有MC的兄弟姐妹相比,aHR为2.04(95%CI = 1.18-3.56)。结论:与普通人群相比,MC患者患RA的风险几乎是普通人群的两倍。了解这种增加的风险可能会加快对出现关节症状和/或关节痛的MC患者的RA评估,从而防止延迟到RA诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease? Editorial: Updated COVID-19 Boosters-Tailoring Protection for Patients With IBD. Authors' Reply. Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach. Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1